Semmax Financial Advisors Inc. reduced its stake in GlaxoSmithKline plc (NYSE:GSK) by 52.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,542 shares of the pharmaceutical company’s stock after selling 13,992 shares during the period. Semmax Financial Advisors Inc.’s holdings in GlaxoSmithKline were worth $524,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. D Orazio & Associates Inc. grew its position in shares of GlaxoSmithKline by 200.0% during the first quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 400 shares in the last quarter. Claybrook Capital LLC acquired a new position in shares of GlaxoSmithKline during the fourth quarter worth about $26,000. Berman Capital Advisors LLC acquired a new position in shares of GlaxoSmithKline during the fourth quarter worth about $32,000. Orrstown Financial Services Inc. grew its position in shares of GlaxoSmithKline by 210.7% during the first quarter. Orrstown Financial Services Inc. now owns 932 shares of the pharmaceutical company’s stock worth $39,000 after buying an additional 632 shares in the last quarter. Finally, Riverview Trust Co acquired a new position in shares of GlaxoSmithKline during the first quarter worth about $39,000. Hedge funds and other institutional investors own 11.12% of the company’s stock.
Shares of GSK opened at $39.46 on Friday. The company has a debt-to-equity ratio of 6.92, a current ratio of 0.72 and a quick ratio of 0.48. The company has a market capitalization of $97.88 billion, a P/E ratio of 12.49, a price-to-earnings-growth ratio of 2.04 and a beta of 0.74. GlaxoSmithKline plc has a 52-week low of $36.41 and a 52-week high of $42.36.
A number of equities analysts have recently commented on GSK shares. UBS Group downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Friday, February 22nd. Shore Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Finally, Zacks Investment Research raised GlaxoSmithKline from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $41.83.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 325,000 shares of the stock in a transaction that occurred on Monday, April 22nd. The stock was purchased at an average cost of $18.00 per share, with a total value of $5,850,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Shares Sold by Semmax Financial Advisors Inc.” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2019/05/19/glaxosmithkline-plc-gsk-shares-sold-by-semmax-financial-advisors-inc.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Why is cost of goods sold important?
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.